Multiple Sclerosis Clinical Trials in Phoenix

Showing 201-220 of 268 trials

Registry Trial to Determine pCLE Image Interpretation Criteria and Preliminary Accuracy in the Lung

NCT01793246

Patients will be enrolled that are undergoing bronchoscopy for diagnosis of discrete lung lesions or for detection of acute rejection following lung transplants. The hypothesis is that bronchoscopy together with probe-based endomicroscopy (pCLE)results in improved and/or incremental diagnostic yield (definitive diagnosis) over conventional bronchoscopy.

Lung NeoplasmsDisorder Related to Lung Transplantation

Mauna Kea Technologies99 participantsStarted Feb 2013

Phoenix, Arizona, United States • Jacksonville, Florida, United States • Chicago, Illinois, United States +6 more locations

COMPLETEDPHASE2< 1 mile

Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment

NCT02471222

This is a multi-center, randomized, double-blind, placebo-controlled, 2-arm, parallel group study of ADS-5102 extended release (ER) capsules, an investigational formulation of amantadine, dosed once daily at bedtime for the treatment of walking impairment in MS. ADS-5102 is designed to be administered once daily at bed time, ADS-5102 achieves higher plasma amantadine concentrations in the early morning, sustained throughout the afternoon, and lower concentrations in the evening when patients are sleeping. ADS-5102 is designed to deliver its primary treatment effect during the day, and potentially reduce the adverse events of immediate-release amantadine when the patient is asleep.

Walking ImpairmentMultiple Sclerosis

Adamas Pharmaceuticals, Inc.60 participantsStarted May 2015

Phoenix, Arizona, United States • Aurora, Colorado, United States • Sarasota, Florida, United States +12 more locations

Registry Trial to Determine pCLE Image Interpretation Criteria and Preliminary Accuracy in the Lung

Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment

Multiple Sclerosis Trials in Other Cities

Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis

Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)

Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States

Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis

A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers

Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer

Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.

Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib

Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo-Controlled Phase-III STudy

Efficacy and Safety of GTR in Comparison to Copaxone®

EPO906 Therapy in Patients With Prostate Cancer

A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer

Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients

A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation

An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies

JC-Virus (JCV) Antibody Program

BIBW 2992 (Afatinib) in Head & Neck Cancer

Zenith(R) Fenestrated Abdominal Aortic Aneurysm (AAA) Endovascular Graft Clinical Study

Other Conditions in Phoenix